Your dog was diagnosed with Hepatocellular Carcinoma. Most common primary hepatic tumour in dogs. Three morphological forms: massive (single large mass — ~55%, best prognosis), nodular (multiple nodules — ~30%), diffuse (~15%, worst prognosis). Many are incidental findings on abdominal imaging. Compare 3 treatment options for dogs including Liver Lobectomy (Massive Form), Systemic Chemotherapy (Unresectable), Supportive Care / Palliation — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Hepatocellular Carcinoma
Canine Oncology Treatment Guide
Hepatocellular Carcinoma
Epithelial
About This Cancer
Hepatocellular carcinoma is the most common primary liver cancer in dogs, arising from hepatocytes — the main functional cells of the liver. It occurs in three distinct forms: massive (a single large tumour in one liver lobe, about 55% of cases), nodular (multiple tumour nodules across the liver, about 30%), and diffuse (cancer spread throughout the liver, about 15%). This distinction is critically important because the massive form can often be cured by surgically removing the affected liver lobe, whereas the nodular and diffuse forms are generally not amenable to complete surgical removal. Many hepatocellular carcinomas are discovered incidentally during imaging for other reasons, as they can grow to a substantial size before causing clinical signs. When symptoms do develop, they may include lethargy, reduced appetite, weight loss, or abdominal distension. The liver has remarkable regenerative capacity, and dogs typically recover well from surgical removal of even a large portion.
Morphological classification
Canine HCC classified by morphological pattern rather than formal TNM staging
Prognostic Factors(3)
Minimum Workup(7 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.